Medplus Health Services Q3FY26 Revenue Rises 15.7% YoY to ₹18,061 Crore
Medplus Health Services reported Q3 FY2026 revenue of ₹18,061 million, up 15.7% YoY. Gross Margin increased by 110 bps to 26.2%. The company added 182 net stores, reaching a total of 5,112. Operating Cash Flow was ₹905 million. An investor presentation detailed these results.
The announcement provides key financial results for the quarter, including revenue growth and margin expansion, which are material information for investors and significantly impact the company's valuation and investor perception.
The company reported strong year-on-year growth in revenue and gross margin, along with a healthy increase in store count and positive operating cash flow, indicating a positive financial performance.
Medplus Health Services Limited announced its un-audited financial results for the quarter ended December 31, 2025. The company reported a revenue of ₹18,061 million (₹1,806.1 crore), marking a 15.7% year-on-year increase from ₹15,614 million in Q3 FY2025 and a 7.5% increase from ₹16,793 million in Q2 FY2026.
Gross Margin stood at ₹4,724 million, representing a 26.2% Gross Margin percentage, an increase of 110 basis points year-on-year. Pharmacy Operating EBITDA was ₹925 million, with a 5.2% operating EBITDA margin. Company Operating EBITDA reached ₹968 million, and Operating Cash Flow was ₹905 million, which is 93.5% of Operating EBITDA.
The company added 182 stores in the quarter (228 gross additions), bringing the total store count to 5,112 as of December 31, 2025. Stores older than 12 months showed a 10.5% revenue growth year-on-year, with a 12.4% Store Level EBITDA margin and 77.7% Store Level Operating ROCE.
The investor presentation also highlighted the company's cluster-based expansion strategy and its omni-channel capabilities, emphasizing a strong network of stores enabling efficient delivery and lower customer acquisition costs. The private label segment continues to grow, with over 1,500 SKUs contributing to higher margins and wallet share.
The earnings call to discuss these results was scheduled for Monday, February 02, 2026, at 16:00 Hrs (IST).
What to do with a filing like this
Medplus Health Services Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Medplus Health Services Limited. Read the original for the full detail.